13F-HR 1 form13fhr.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for the Calendar Year or Quarter Ended: 12/31/2010 Check here if Amendment []; Amendment Number: ------- This Amendment (Check only one.): [] is a restatement. [] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Ridgeback Capital Investments L.P. Address: 430 Park Avenue, 12th Floor New York, New York 10022 Form 13F File Number: 28-12856 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Persons Signing this Report on Behalf of Reporting Manager: Name: Ridgeback Capital Investments Ltd., as General Partner, by Bud Holman Title: Director Phone: 212-808-7729 Signature, Place, and Date of Signing: /s/ Bud Holman New York, New York 2/14/2011 --------------------------------- --------------------------------- ---------- [Signature] [City, State] [Date] Ridgeback Capital Investments Ltd. is the general partner of Ridgeback Capital Investments L.P. Pursuant to an investment management agreement, Ridgeback Capital Management LP maintains investment and voting power with respect to the securities held or controlled by Ridgeback Capital Investments Ltd. Wayne Holman, an individual, controls Ridgeback Capital Management LP. Ridgeback Capital Management LP, Ridgeback Capital Investments Ltd. and Wayne Holman do not own any securities reported herein directly. Report Type (Check only one): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 2 Form 13F Information Table Entry Total: 10 Form 13F Information Table Value Total: $ 353,202 -------------- (In Thousands) List of Other Included Managers: Provide a numbered list of the name(s) and 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. No. Form 13F File Number Name 1 28-12280 Ridgeback Capital Management LP ---- -------------------- ---------------------------------------------------- 2 28-12277 Ridgeback Capital Investments Ltd. ---- -------------------- ----------------------------------------------------
FORM 13F INFORMATION TABLE COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 ------------------------------- -------------- --------- -------- ------------------ ---------- -------- --------------------- VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE ------------------------------- -------------- --------- -------- --------- --- ---- ---------- -------- ---- ------ --------- Beckman Coulter, Inc. Common Stock 075811109 26,404 350,976 SH SOLE 1,2 0 0 350,976 BioMarin Pharmaceuticals Inc. Common Stock 09061G101 51,862 1,925,800 SH SOLE 1,2 0 0 1,925,800 GlaxoSmithKline plc Sponsored ADR 37733W105 35,549 906,400 SH SOLE 1,2 0 0 906,400 InterMune Inc. Common Stock 45884X103 14,571 400,300 SH SOLE 1,2 0 0 400,300 King Pharmaceuticals Inc. Common Stock 495582108 43,696 3,110,000 SH SOLE 1,2 0 0 3,110,000 The Medicines Company Common Stock 584688105 68,246 4,829,900 SH SOLE 1,2 0 0 4,829,900 Onyx Pharmaceuticals, Inc. Common Stock 683399109 70,010 1,898,826 SH SOLE 1,2 0 0 1,898,826 Regeneron Pharmaceuticals, Inc. Common Stock 75886F107 7,329 223,252 SH SOLE 1,2 0 0 223,252 Pharmasset, Inc. Common Stock 71715N106 31,166 715,464 SH SOLE 1,2 0 0 715,464 YM BioSciences Inc. Common Stock 984238105 4,369 1,875,000 SH SOLE 1,2 0 0 1,875,000